News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement
|Articles|August 10, 2010

EGA Talks Biosimilars

The European Generic Medicines Association's Director for Scientific Affairs, Suzette Cox, talks to us about the environment for biosimilars.

Advertisement

Click here.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement
Global
|
R&D/Clinical Trials

Related Content

Advertisement

Andrew Hall: The Discipline of Conviction

ByMichael Christel
March 13th 2026
Stock.adobe.com

FDA Reveals New Guidance for Streamlining Biosimilar Development

ByNicholas Jacobus
March 11th 2026

JCA vs. Reality: Europe’s Push for Clinical Harmonization

ByDmitry Goldenberg ,Diane Cosset ,Eleonora Sirena
March 10th 2026
Stock.adobe.com

How FDA's Removal of the Two-Trial Requirement Affects Development Programs

ByNicholas Jacobus,Ron Lanton
March 10th 2026
Stock.adobe.com

Ipsen Withdraws Tazverik from Market Due to Emerging Data from Clinical Trial

ByNicholas Jacobus
March 9th 2026
Advertisement
Advertisement

Trending on PharmExec

1

Eli Lilly Releases Open Letter Warning of Potential Safety Risks for Compounded Tirzepatide Plus Vitamin B12

2

What is Shadow AI and How is it Impacting Pharma Companies?

3

Novo Nordisk Responds to FDA’s Warning Letter Regarding 2025 PADE Inspection

4

Agentic AI and the Future of Commercial Excellence in Life Sciences

5

Pharmaceutical Executive Daily: FDA Expands Approval for Arexvy

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us